141 related articles for article (PubMed ID: 34731765)
41. Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonism.
Oestreich JH; Ferraris SP; Steinhubl SR; Akers WS
Thromb Res; 2013 Feb; 131(2):e64-70. PubMed ID: 23245937
[TBL] [Abstract][Full Text] [Related]
42. Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors.
Badr Eslam R; Lang IM; Koppensteiner R; Calatzis A; Panzer S; Gremmel T
Int J Cardiol; 2013 Sep; 168(1):403-6. PubMed ID: 23041015
[TBL] [Abstract][Full Text] [Related]
43. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
44. Platelet P2Y₁₂ blockers confer direct postconditioning-like protection in reperfused rabbit hearts.
Yang XM; Liu Y; Cui L; Yang X; Liu Y; Tandon N; Kambayashi J; Downey JM; Cohen MV
J Cardiovasc Pharmacol Ther; 2013 May; 18(3):251-62. PubMed ID: 23233653
[TBL] [Abstract][Full Text] [Related]
45. Platelet Inhibition Agents: Current and Future P2Y12 Receptor Antagonists.
Tang J; Li MP; Zhou HH; Chen XP
Curr Vasc Pharmacol; 2015; 13(5):566-77. PubMed ID: 25440595
[TBL] [Abstract][Full Text] [Related]
46. Simultaneous Platelet P2Y12 and P2Y1 ADP Receptor Blockade: Are Two Better Than One?
Vaduganathan M; Bhatt DL
Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):427-8. PubMed ID: 26912743
[No Abstract] [Full Text] [Related]
47. Effect of P2Y1 and P2Y12 genetic polymorphisms on the ADP-induced platelet aggregation in a Korean population.
Kim KA; Song WG; Lee HM; Joo HJ; Park JY
Thromb Res; 2013 Aug; 132(2):221-6. PubMed ID: 23849096
[TBL] [Abstract][Full Text] [Related]
48. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y
Boncler M; Wzorek J; Wolska N; Polak D; Watala C; Rozalski M
Vascul Pharmacol; 2019 Feb; 113():47-56. PubMed ID: 30471364
[TBL] [Abstract][Full Text] [Related]
49. Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy.
Bagoly Z; Sarkady F; Magyar T; Kappelmayer J; Pongrácz E; Csiba L; Muszbek L
PLoS One; 2013; 8(7):e69417. PubMed ID: 23844259
[TBL] [Abstract][Full Text] [Related]
50. Aspirin, P2Y12 blockers, cilostazol, PAR-1 blockers and emerging antiplatelet therapies: can biomarkers guide clinical development and practice?
Menown IB
Biomark Med; 2011 Feb; 5(1):1-3. PubMed ID: 21319960
[No Abstract] [Full Text] [Related]
51. Structure of the human P2Y12 receptor in complex with an antithrombotic drug.
Zhang K; Zhang J; Gao ZG; Zhang D; Zhu L; Han GW; Moss SM; Paoletta S; Kiselev E; Lu W; Fenalti G; Zhang W; Müller CE; Yang H; Jiang H; Cherezov V; Katritch V; Jacobson KA; Stevens RC; Wu B; Zhao Q
Nature; 2014 May; 509(7498):115-8. PubMed ID: 24670650
[TBL] [Abstract][Full Text] [Related]
52. P2Y12 receptor antagonists in acute coronary syndrome: clinical implications of pharmacologic and pharmacogenetic differences.
Singh M; Adigopula S; Ahmad N; Arora R; Khosla S
Recent Pat Cardiovasc Drug Discov; 2011 Sep; 6(3):207-14. PubMed ID: 21861826
[TBL] [Abstract][Full Text] [Related]
53. Pharmacology and structure of P2Y receptors.
von Kügelgen I; Hoffmann K
Neuropharmacology; 2016 May; 104():50-61. PubMed ID: 26519900
[TBL] [Abstract][Full Text] [Related]
54. A complementary role for tetraspanin superfamily member TSSC6 and ADP purinergic P2Y
Makkawi M; Howells D; Wright MD; Jackson DE
Thromb Res; 2018 Jan; 161():12-21. PubMed ID: 29178985
[TBL] [Abstract][Full Text] [Related]
55. Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists.
Price MJ; Barker CM
Biomark Med; 2011 Feb; 5(1):43-51. PubMed ID: 21319964
[TBL] [Abstract][Full Text] [Related]
56. Designing Natural Product Hybrids Bearing Triple Antiplatelet Profile and Evaluating Their Human Plasma Stability.
Tsiailanis A; Tsoumani M; Stylos EK; Chatziathanasiadou MV; Kellici TF; Mavromoustakos T; Tselepis AD; Tzakos AG
Methods Mol Biol; 2018; 1824():371-385. PubMed ID: 30039419
[TBL] [Abstract][Full Text] [Related]
57. Pleiotropic effects of platelet P2Y12 receptor inhibitors: fact or fiction?
Moulias A; Xanthopoulou I; Alexopoulos D
Curr Pharm Des; 2014; 20(28):4597-604. PubMed ID: 24730531
[TBL] [Abstract][Full Text] [Related]
58. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.
Ferri N; Corsini A; Bellosta S
Drugs; 2013 Oct; 73(15):1681-709. PubMed ID: 24114622
[TBL] [Abstract][Full Text] [Related]
59. P2Y
Mansour A; Bachelot-Loza C; Nesseler N; Gaussem P; Gouin-Thibault I
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32092903
[TBL] [Abstract][Full Text] [Related]
60. High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
Björkman JA; Zachrisson H; Forsberg GB; von Bahr H; Hansson GI; Warner TD; Nylander S
Thromb Res; 2013 Apr; 131(4):313-9. PubMed ID: 23419412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
